They found that a fraction of patients deemed as having an unmethylated tumor (score 1 to 1.99) had survival similar to those considered to be methylated (score ≥2), whereas those with a score less than 1 had poorer outcome.38 This is confirmed in a recent publication indicating that patients with MGMT status determined by msPCR with results between clearly methylated and unmethylated (gray zone) seem to benefit from TMZ treatment.39 The gene discussed is MGMT; the disease is neoplasm.